With Zero Revenue, Laekna Plays Chicken-And-Egg Game With Investors
The biotechnology company, which is facing ballooning losses without any revenue like many of its peers, has filed for an IPO in Hong Kong (more…)
FAST NEWS: Vaccine Maker Jiangsu Recbio Gets Little Boost on Listing Day
The latest: Jiangsu Recbio Technology Co. Ltd (2179.HK), a producer of human papillomavirus (HPV) vaccines, received a muted reception as it made its trading debut in Hong Kong on Thursday.…
Jiangsu Recbio Shoots to Become Hong Kong’s First HPV Vaccine Stock
The vaccine producer is making a second attempt to list in Hong Kong, as its core HPV vaccine undergoes Phase 3 clinical trials Key takeaways: Jiangsu Recbio has filed a…
RECENT ARTICLES
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK -
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
- Waton plays up fintech transformation, though without much evidence
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
-
Investors cheer Akeso’s revenue milestone, even as it returns to the red
9926.HK
-
Cash-hungry Mabwell seeks financial tonic from Hong Kong investors
688062.SHG
